Back

Prevalence of subclinical coronary artery atherosclerosis in the general population- apollo subclinical coronary atherosclerosis project (ASCAP)

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk assessment (1) Cardiovascular Risk Assessment ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Lavanya Narra

Krishna Institute of Medical Sciences Kondapur, Hyderabad (India)

5 More presentations in this session

Presentation thumbnail
Inferior vena cava wall thickness is associated with the presence and severity of cardiovascular disease.
Doctor K. Fujiyoshi (Kanagawa, JP)
Abstract Slides Video
Presentation thumbnail
Typical and atypical chest pain: an equivocal and dangerous definition
Doctor D. Cosmi (Perugia, IT)
Abstract Slides Video
Presentation thumbnail
Influence of Lp(a) and systemic inflammation on all-cause mortality in a primary prevention population: data from our clinic database
Doctor L. Cho (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Non-HDL cholesterol and residual risk of myocardial infarction and death in statin-treated patients with and without diabetes
Doctor M. Hansen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Carotid plaque score for stroke and cardiovascular risk prediction in a middle-aged cohort from the general population: the akershus cardiac examination 1950 study
Mr H. Ihle-Hansen (Gjettum, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular risk assessment (1)

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
Saving hearts, extending lives: the impact of risk prevention on lifetime estimates in Germany

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources